Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,908,275
  • Shares Outstanding, K 21,250
  • Annual Sales, $ 141,100 K
  • Annual Income, $ 12,560 K
  • 36-Month Beta 1.49
  • Price/Sales 21.36
  • Price/Cash Flow 37.60
  • Price/Book 4.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.99
  • Number of Estimates 1
  • High Estimate 0.99
  • Low Estimate 0.99
  • Prior Year 1.03
  • Growth Rate Est. (year over year) -3.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.55 +0.97%
on 12/14/18
166.52 -17.81%
on 11/30/18
-10.94 (-7.40%)
since 11/14/18
3-Month
135.55 +0.97%
on 12/14/18
278.62 -50.88%
on 10/01/18
-117.93 (-46.29%)
since 09/14/18
52-Week
133.45 +2.56%
on 12/15/17
278.62 -50.88%
on 10/01/18
+0.82 (+0.60%)
since 12/14/17

Most Recent Stories

More News
Ligand Pharm Falls 3.37% on Heavy Volume: Watch For Potential Rebound

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $141.28 to a high of $149.05. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $144.30...

LGND : 136.86 (-3.47%)
Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that the U.S. Food and Drug...

LGND : 136.86 (-3.47%)
Why Is Ligand (LGND) Down 14.9% Since Last Earnings Report?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LGND : 136.86 (-3.47%)
Detailed Research: Economic Perspectives on American Tower Corporation (REIT), Ligand Pharmaceuticals, Teva Pharmaceutical Industries, Cummins, Alexander's, and Korea Electric Power -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of American Tower Corporation...

LGND : 136.86 (-3.47%)
KEP : 14.33 (+0.92%)
AMT : 166.60 (-0.12%)
TEVA : 18.46 (-2.94%)
ALX : 308.35 (unch)
CMI : 133.84 (-0.47%)
Interesting LGND Put And Call Options For January 2019

Investors in Ligand Pharmaceuticals Inc saw new options become available this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the LGND...

LGND : 136.86 (-3.47%)
Ligand Announces OmniAb(R) Partnership with iMetabolic Biopharma Corporation

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with iMetabolic Biopharma Corporation (iMBP), an early stage biopharma company...

LGND : 136.86 (-3.47%)
Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium

Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo model,...

LGND : 136.86 (-3.47%)
After Yesterday's Decline of 2.14%, Ligand Pharm Offers Investors Better Value

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $147.96 to a high of $158.08. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $154.25...

LGND : 136.86 (-3.47%)
Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo

Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo)...

LGND : 136.86 (-3.47%)
Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View

Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.

SPPI : 11.58 (unch)
LGND : 136.86 (-3.47%)
NVS : 87.39 (-1.14%)
AMGN : 192.07 (-2.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade LGND with:

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 146.11
1st Resistance Point 141.48
Last Price 136.86
1st Support Level 133.89
2nd Support Level 130.93

See More

52-Week High 278.62
Fibonacci 61.8% 223.17
Fibonacci 50% 206.04
Fibonacci 38.2% 188.90
Last Price 136.86
52-Week Low 133.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar